LFB chooses Technip as prime-contractor for “Usine 2020”
LFB BIOMEDICAMENTS appoints Technip prime-contractor for the construction of their next-generation plant, “Usine 2020”, in Arras (Northern France)
Les Ulis, 31st March 2016 – LFB BIOMEDICAMENTS, a wholly-owned subsidiary of LFB SA, announces the signing of a services agreement with Technip, making them their prime-contractor for the LFB “Usine 2020” project. Technip will be the prime-contractor, responsible for design, construction and qualification of LFB’s next-generation plant near Arras (Pas-de-Calais), which is due to be completed by 2020.
“Usine 2020” would allow LFB to triple their global production of plasma-derived medicinal products within the next ten years, especially in the field of immunoglobulins, albumin and fibrinogen. Combining all phases of production of these medicinal products, from plasma fractionation up to the aseptic packaging of both liquid and lyophilisate products, this next-generation plant is designed to meet the highest international standards in this very specialized branch of biopharmaceuticals.
Located on a 16-hectare site within the Actiparc industrial park in the Urban Community of Arras, this next-generation plant amounts to an investment of around 300 million euros.
“This new plant will enable LFB in France to significantly step up its production of essential medicinal products for the treatment of serious and often rare diseases around the world”, sums up Denis Soubeyran, General Director of LFB BIOMEDICAMENTS. “With Technip as our partner in this project, we chose a well-known French company whose experience and commitment inspire confidence to go ahead with this major LFB development”.
Technip is also the prime-contractor for a new plasma thawing system at the LFB site of Les Ulis and has previously supported LFB’s efforts to double their production capacity at Les Ulis between 2007 and 2010.
Construction of “Usine 2020” commences in the first half of 2016, with Technip as prime-contractor. The building is expected to be completed by the end of 2017, with the qualified plant to be fully operational in 2020 and the first commercial batches of medicinal products produced that same year.
About the LFB Group LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products from biological sources for the treatment of serious and often rare diseases in major therapeutic areas, including haemostasis, immunology and intensive care. Number one in France and sixth in the world for plasma-derived medicinal products, the LFB group is also one of the leading European companies in the development and production of proteins and innovative treatment derived from biotechnologies. Relying on its sustained research efforts, the LFB group is implementing a growth strategy to expand its activities to international markets. The LFB group currently markets products in 40 countries throughout the world and achieved a global turnover of 502 million euros in 2014. It employs more than 2,000 people.
Media Contacts
Sandrine Charrières
Executive Vice-President, Corporate Communications
Phone: +33 (1) 69 82 72 80
email : charrieres@lfb.fr
Jeanne Bariller
Havas Worldwide
Phone : +33 (6) 15 51 49 40
email : jeanne.bariller@havasww.com